Disease Mongering and the Disorientation of Science. Is it Possible that the Scientific Method is Being Diverted to Commercial Ends?
DOI:
https://doi.org/10.14738/bjhr.1305.12207Keywords:
Disease mongering, medicalization, scientific method, pharmaceutical industry, overdiagnosisAbstract
Disease mongering is the process, supported by marketing and healthcare communication campaigns, through which minor ailments, mild disorders, or normal physiological conditions are transformed—for commercial purposes—into actual pathologies. The goal is to artificially and commercially convert healthy people into sick individuals, into patients who "consume" drugs and diagnostic tests. This conversion occurs by lowering clinical parameters or even inventing "false diseases." The process tends to increase medicalization, drug consumption, and the number of therapeutic interventions. The question we ask is this: can this commercial approach significantly disorient science and divert the scientific method primarily toward market interests? To answer our question, we initiated a literature search, using biomedical databases, analyzing the most relevant articles on the topic, and reflecting on the most interesting and significant data. The results of our research clearly demonstrate how disease mongering shapes the very concept and definition of disease, as well as how it influences the production of scientific evidence, medical communication, healthcare training, and the public perception of health. In conclusion, based on the study conducted and the scientific articles reviewed, we believe that the scientific method, if bent to commercial interests, risks losing its epistemic function. In particular, we also believe that disease mongering poses a concrete risk to the integrity of science and public health. In our medical view, we believe it is unscientific to artificially and consumeristically transform healthy people into sick people; therefore, we advocate for serious and determined multidisciplinary countermeasures.
References
Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324(7342):886-891. doi:10.1136/bmj.324.7342.886
Moynihan R, Henry D. The fight against disease mongering: generating knowledge for action.
Wolinsky H. Disease mongering and drug marketing. Does the pharmaceutical industry manufacture diseases as well as drugs?. EMBO Rep. 2005;6(7):612-614. doi:10.1038/sj.embor.7400476 Scholar Publishing
Saddichha S. Disease mongering in psychiatry: fact or fiction?. JNMA J Nepal Med Assoc. 2010;50(180):320-327. https://pubmed.ncbi.nlm.nih.gov/22049901/
Gavilán E, Jiménez de Gracia L, Gérvas J. Estrategias de promoción del síndrome por déficit de testosterone: un caso paradigmatico de invención de enfermedad (disease mongering) [Strategies to promote testosterone deficiency syndrome: a paradigm of disease mongering]. Gac Sanit. 2014;28(2):173-176. doi:10.1016/j.gaceta.2013.06.007
Vance MA. Disease mongering and the fear of pandemic influenza. Int J Health Serv. 2011;41(1):95-115. doi:10.2190/HS.41.1.g
Shankar PR, Giri BR, Palaian S. Fairness creams in South Asia--a case of disease mongering?.
Tiefer L. Female sexual dysfunction: a case study of disease mongering and activist resistance.
Tarro, G., & De Giorgio, G. (2024). Homeopathy in the Treatment of Cancer: A Hope That Must Be Nurtured. British Journal of Healthcare and Medical Research, Vol - 11(6). 264-270.
De Giorgio G, & Tarro G. (2025). Homeopathy in the treatment of Viral Diseases: Scientific Data on the Basis of which it is Possible to Reason Scientifically on the Therapeutic Potential of Homeopathic Medicines. British Journal of Healthcare and Medical Research, Vol - 12(02). 76-81.
Tarro, G. & De Giorgio, G.(2025). In vitro, In vivo Studies and Clinical Studies Provide Significant Results that Facilitate a Scientific Discussion on the Therapeutic Efficacy of Homeopathic Medicines. British Journal of Healthcare and Medical Research, Vol -12(03). 241-267.
De Giorgio, G. & Tarro, G., (2026). Homeopathy and Psychotherapy: Clarifications on Differences and Similarities. A Comparative Analysis of Related but Distinct Disciplines. British Journal of Healthcare and Medical Research; Vol. 13 No. 01 (2026) (316-321) https://doi.org/10.14738/bjhr.1301.19959.
Tarro, G., & De Giorgio, G. (2026). Homeopathy and Diabetes: Current Evidence and Future Prospects. British Journal of Healthcare and Medical Research;Vol. 13 No. 02 (58-64) https://doi.org/10.14738/bjhr.1302.20140 .
Moynihan R, Brodersen J, Heath I, et al. Reforming disease definitions: a new primary care led, people-centred approach. BMJ Evid Based Med. 2019;24(5):170-173. doi:10.1136/bmjebm-2018-111148
Shankar PR, Subish P. Disease mongering. Singapore Med J. 2007;48(4):275-280. https://pubmed.ncbi.nlm.nih.gov/17384871/
Alonso-Coello P, García-Franco AL, Guyatt G, Moynihan R. Drugs for pre-osteoporosis: prevention or disease mongering?. BMJ. 2008;336(7636):126-129. doi:10.1136/bmj.39435.656250.AD
Wright J. Marketing disease: is osteoporosis an example of 'disease mongering'?. Br J Nurs. 2009;18(17):1064-1067. doi:10.12968/bjon.2009.18.17.44163
Frappé P, Haller DM, Roméas A, Bertoletti L, François M, Robert-Ebadi H, Righini M. Avoiding disease mongering: A checklist for vascular physicians and researchers. Thromb Res. 2019;181:120-123. doi:10.1016/j.thromres.2019.08.001
Reddy NK. Redefining disease in the age of blood-based biomarkers. Front Social. 2025;10:1533429. Published 2025 Feb 28. doi:10.3389/fsoc.2025.1533429 Scholar Publishing
Ioannidis JPA. Diagnosis and Treatment of Hypertension in the 2017 ACC/AHA Guidelines and in the Real World. JAMA. 2018;319(2):115-116. doi:10.1001/jama.2017.19672
Sekkarie A, Fang J, Hayes D, Loustalot F. Prevalence of Self-Reported Hypertension and Antihypertensive Medication Use Among Adults - United States, 2017-2021. MMWR Morb Mortal Wkly Rep. 2024;73(9):191-198. Published 2024 Mar 7. doi:10.15585/mmwr.mm7309a1
Petersen M. Inside the plan to diagnose Alzheimer's in people with no memory problems — and who stands to benefit. Los Angeles Times. February 14, 2024. Available at: https://www.latimes.com/science/story/2024-02-14/inside-controversial-plan-to-diagnosealzheimers-in-people-without-symptoms
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297-312. doi:10.1038/s41571-020-00457-x
Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr Dis Treat. 2017;13:1245-1262. Published 2017 May 10. doi:10.2147/NDT.S114542
Cronjé HT, Mi MY, Austin TR, et al. Plasma Proteomic Risk Markers of Incident Type 2 Diabetes Reflect Physiologically Distinct Components of Glucose-Insulin Homeostasis. Diabetes. 2023;72(5):666-673. doi:10.2337/db22-0628
Yadava OP. Do we need new reporting norms? Indian J Thorac Cardiovasc Surg. 2025;41:123-125. doi:10.1007/s12055-024-01888-2.
Breitstein, J. The making of a new disease. Pharma Exec, 1. 2004. https://www.pharmexec.com/view/making-new-disease
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Giulio Tarro, Giovanni De Giorgio

This work is licensed under a Creative Commons Attribution 4.0 International License.